

<b>NCT ID</b>	NCT02298959
<b>Title</b>	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2014-11-24
<b>Location</b>	Florida, United States Maryland, United States Massachusetts, United States Canada
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02285816
<b>Title</b>	MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2014-11-07
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AdMA3, MG1MA3
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02215889
<b>Title</b>	Partial Liver Segment 2/3 Transplantation Study
<b>Phase</b>	Phase 1
<b>Date Added</b>	2014-08-13
<b>Location</b>	Norway
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT01697371
<b>Title</b>	Proton Therapy in the Treatment of Liver Metastases
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2012-10-02
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT01351103
<b>Title</b>	A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
<b>Phase</b>	Phase 1

<b>Date Added</b>	2011-05-10
<b>Location</b>	California, United States Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canada France Germany Italy Netherlands Spain
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	LGK974, PDR001
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT01174121
<b>Title</b>	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2010-08-03
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT01061515
<b>Title</b>	Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2010-02-03
<b>Location</b>	Missouri, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT00001823
<b>Title</b>	Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
<b>Phase</b>	
<b>Date Added</b>	1999-11-04
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	LUMINESCENCE

<b>Title</b>	Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-01-25
<b>Location</b>	
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy
<b>Tags</b>	MSS/ MMRp